MedPath

Identification of Sentinel Lymph Nodes With Methylene Blue and Isotope

Not Applicable
Completed
Conditions
Infiltrative Breast Cancer
Registration Number
NCT00314405
Lead Sponsor
University Hospital, Strasbourg, France
Brief Summary

The aim of this study is to evaluate the performance of a double labelling method using isotope and methylene blue dye injection to localize precisely Sentinel Lymph Node (SLN) in a series of 100 patients with infiltrative breast cancer justifying SLN excision. Method and patients: SLN excision will be performed on 100 patients treated for infiltrative breast cancer. After preoperative methylene blue dye injection and lymphoscintigraphy, individual localization of the radioactive and stained nodes will be performed. After the surgery, SLN will be submitted to serial analysis and immunohistochemistry. A comparison of the two methods and an economical evaluation of the complete procedure will be performed.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
100
Inclusion Criteria
  • patients with infiltrative breast cancer (diagnosed pre-operatively by core biopsy)
  • approval and informed consent
Exclusion Criteria
  • chemotherapy
  • locoregional radiotherapy
  • prevalent axillary lymph node

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Determination of an optimized protocol for SLN identification, with a double method using isotope and methylene blue dye injection.
Secondary Outcome Measures
NameTimeMethod
Comparison of the results of SLN serial sectioning, with H&E and IHC staining
Economical evaluation of SLN procedure.

Trial Locations

Locations (1)

Service de Gynécologie-Obstétrique, Hôpital Civil

🇫🇷

Strasbourg, France

Service de Gynécologie-Obstétrique, Hôpital Civil
🇫🇷Strasbourg, France
© Copyright 2025. All Rights Reserved by MedPath